Company profile IMAB
After 38 days of this quarter the interest is at 69.0. Based on that we can calculate that during remaining 53 days it will total up to 165.0. I-Mab expected interest is significantly higher compared to previous quarter (+153.8%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 40 | 50 25.0% QoQ | 70 40.0% QoQ | 96 37.1% QoQ |
| 2020 | 169 322.5% YoY 76.0% QoQ | 169 238.0% YoY 0.0% QoQ | 88 25.7% YoY -47.9% QoQ | 109 13.5% YoY 23.9% QoQ |
| 2021 | 131 -22.5% YoY 20.2% QoQ | 123 -27.2% YoY -6.1% QoQ | 62 -29.5% YoY -49.6% QoQ | 152 39.4% YoY 145.2% QoQ |
| 2022 | 204 55.7% YoY 34.2% QoQ | 168 36.6% YoY -17.6% QoQ | 127 104.8% YoY -24.4% QoQ | 46 -69.7% YoY -63.8% QoQ |
| 2023 | 148 -27.5% YoY 221.7% QoQ | 53 -68.5% YoY -64.2% QoQ | 113 -11.0% YoY 113.2% QoQ | 65 41.3% YoY -42.5% QoQ |
| 2024 | 69 -53.4% YoY 6.2% QoQ | - | - | - |
There is not enough data for I-Mab to provide correlation calculation
The average 5 years interest of I-Mab was 8.66 per week. The last year interest of I-Mab compared to the last 5 years has changed by -0.46%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 29.62%.
After 38 days of this quarter the interest is at 55.0. Based on that we can calculate that during remaining 53 days it will total up to 132.0. I-Mab biopharma expected interest is significantly higher compared to previous quarter (+43.5%) and same quarter last year (+57.1%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 87 inf% QoQ | 100 14.9% QoQ | 106 6.0% QoQ |
| 2020 | 95 inf% YoY -10.4% QoQ | 43 -50.6% YoY -54.7% QoQ | 158 58.0% YoY 267.4% QoQ | 87 -17.9% YoY -44.9% QoQ |
| 2021 | 103 8.4% YoY 18.4% QoQ | 147 241.9% YoY 42.7% QoQ | 84 -46.8% YoY -42.9% QoQ | 214 146.0% YoY 154.8% QoQ |
| 2022 | 58 -43.7% YoY -72.9% QoQ | 50 -66.0% YoY -13.8% QoQ | 233 177.4% YoY 366.0% QoQ | 154 -28.0% YoY -33.9% QoQ |
| 2023 | 84 44.8% YoY -45.5% QoQ | 60 20.0% YoY -28.6% QoQ | 107 -54.1% YoY 78.3% QoQ | 92 -40.3% YoY -14.0% QoQ |
| 2024 | 55 -34.5% YoY -40.2% QoQ | - | - | - |
There is not enough data for I-Mab biopharma to provide correlation calculation
The average 5 years interest of I-Mab biopharma was 8.14 per week. The last year interest of I-Mab biopharma compared to the last 5 years has changed by -10.44%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 13.2%.
After 38 days of this quarter the interest is at 58.0. Based on that we can calculate that during remaining 53 days it will total up to 139.0. I-Mab stock expected interest is significantly higher compared to same quarter last year (+127.9%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 57 | 104 82.5% QoQ | 134 28.8% QoQ | 111 -17.2% QoQ |
| 2020 | 121 112.3% YoY 9.0% QoQ | 248 138.5% YoY 105.0% QoQ | 114 -14.9% YoY -54.0% QoQ | 181 63.1% YoY 58.8% QoQ |
| 2021 | 0 -100.0% YoY -100.0% QoQ | 145 -41.5% YoY inf% QoQ | 107 -6.1% YoY -26.2% QoQ | 318 75.7% YoY 197.2% QoQ |
| 2022 | 138 inf% YoY -56.6% QoQ | 76 -47.6% YoY -44.9% QoQ | 160 49.5% YoY 110.5% QoQ | 52 -83.6% YoY -67.5% QoQ |
| 2023 | 61 -55.8% YoY 17.3% QoQ | 116 52.6% YoY 90.2% QoQ | 194 21.2% YoY 67.2% QoQ | 105 101.9% YoY -45.9% QoQ |
| 2024 | 58 -4.9% YoY -44.8% QoQ | - | - | - |
There is not enough data for I-Mab stock to provide correlation calculation
The average 5 years interest of I-Mab stock was 10.0 per week. The last year interest of I-Mab stock compared to the last 5 years has changed by -5.2%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 6.52%.
There is not enough data for I-Mab pharma to provide analysis
There is not enough data for I-Mab pharma to provide correlation calculation
There is not enough data for I-Mab pharma to provide analysis
There is not enough data for I-Mab antibody to provide analysis
There is not enough data for I-Mab antibody to provide correlation calculation
There is not enough data for I-Mab antibody to provide analysis
There is not enough data for I-Mab company to provide analysis
There is not enough data for I-Mab company to provide correlation calculation
There is not enough data for I-Mab company to provide analysis
There is not enough data for I-Mab news to provide analysis
There is not enough data for I-Mab news to provide correlation calculation
There is not enough data for I-Mab news to provide analysis
There is not enough data for I-Mab clinical trials to provide analysis
There is not enough data for I-Mab clinical trials to provide correlation calculation
There is not enough data for I-Mab clinical trials to provide analysis
There is not enough data for I-Mab cancer treatment to provide analysis
There is not enough data for I-Mab cancer treatment to provide correlation calculation
There is not enough data for I-Mab cancer treatment to provide analysis
There is not enough data for I-Mab autoimmune disorders to provide analysis
There is not enough data for I-Mab autoimmune disorders to provide correlation calculation
There is not enough data for I-Mab autoimmune disorders to provide analysis